Endothelial TAK1 Signaling and Resolution of Pulmonary Edema in Sepsis

脓毒症肺水肿的内皮 TAK1 信号转导和解决

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Sepsis associated with acute lung injury (ALI) is a common cause of death in hospitalized patients. ALI is in large part the result of lung vascular leakage and protein rich edema and there is a lack of effective therapy. Here, we have proposed a novel strategy to reverse ALI by stimulating an endogenous recovery process that is usually activated after lung injury. Thrombin, an edema-genic factor generated during sepsis, mediates pulmonary vascular leakage by activating protease-activated receptor-1 (PAR-1) on the endothelial cell surface. PAR-1-induced Ca2+ entry via store-operated Ca2+-entry channels (SOCs), disassembles endothelial adherens junctions (AJs) to cause increased lung vascular leak. An endoplasmic reticulum (ER) localized Ca2+ sensor protein stromal interacting molecule-1 (STIM1), is crucial for activating SOC to induce store- operated Ca2+-entry (SOCE) in endothelial cells (ECs). Now, we have identified in a murine model of tamoxifen-inducible endothelial cell (EC)-restricted TAK1 (Map3k7) deletion (Map3k7i∆EC), a key role for TAK1 in resolving PAR-1-mediated pulmonary edema formation through regulation of the functions of STIM1, glycogen synthase kinase-3β (GSK-3β) and β-catenin in ECs. We made the following observations (Supporting Data): i) TAK1 null ECs exhibited augmented SOCE and permeability in response to PAR-1 activation; ii) PAR-1-induced lung vascular permeability in vivo was not reversible in Map3k7i∆EC mice; iii) β- catenin expression was markedly reduced in ECs of Map3k7i∆EC mice; iv) glycogen synthase kinase-3β (GSK- 3β) was persistently active in ECs of Map3k7i∆EC mice, which may account for the markedly reduced expression of β-catenin in ECs of Map3k7i∆EC mice; v) PAR-1-medatied TAK1 activation was prevented in ECs of EC-restricted STIM1 knockout (Stim1∆EC) mice; vi) surprisingly, we observed that SOCE signals the inactivation of GSK-3β via TAK1 activation in ECs; vii) importantly, PAR-1-mediated lung vascular leak was markedly reduced in tamoxifen-inducible EC-restricted GSK-3β knockout (GSK-3βi∆EC) mice. Based on these novel observations, in Aim 1, we will test the hypothesis that TAK1 activation secondary to STIM1-mediated SOCE induces STIM1 phosphorylation which in turn inhibits SOCE and dampens lung vascular permeability. In Aim 2, we will test the hypothesis that TAK1 activation secondary to STIM1-mediated SOCE phosphorylates GSK-3β to inactivate GSK-3β, which in turn promotes increased β-catenin expression at endothelial AJs to restore endothelial barrier integrity and thereby resolves pulmonary edema. A better understanding of the signaling mechanisms of TAK1 functions downstream of SOCE will lead to novel therapeutic approaches that will resolve pulmonary edema in sepsis.
 描述(由申请方提供):急性肺损伤(ALI)相关败血症是住院患者死亡的常见原因。ALI在很大程度上是肺血管渗漏和富含蛋白质的水肿的结果,并且缺乏有效的治疗。在这里,我们提出了一种新的策略,通过刺激肺损伤后通常被激活的内源性恢复过程来逆转ALI。凝血酶是脓毒症时产生的一种致水肿因子,通过激活内皮细胞表面的蛋白酶激活受体1(PAR-1)介导肺血管渗漏。PAR-1通过钙池操纵的钙通道(SOC)诱导钙内流,分解内皮粘附连接(AJs),导致肺血管渗漏增加。基质相互作用分子-1(stromal interacting molecule-1,STIM 1)是一种位于内质网(endoplasmic reticulum,ER)的钙传感蛋白,在激活SOC诱导内皮细胞钙池操纵性内流(store-operated Ca~(2+)-entry,SOCE)过程中起重要作用。现在,我们已经在他莫昔芬诱导的内皮细胞(EC)限制性TK 1(Map 3k7)缺失(Map 3k7 i ️ EC)的小鼠模型中确定了TK 1通过调节STIM 1、糖原合成酶的功能在解决PAR-1介导的肺水肿形成中发挥关键作用。EC中的激酶-3 β(GSK-3 β)和β-连环蛋白。我们提出了以下意见(支持数据):i)TAK1无效EC表现出响应PAR-1激活的SOCE和渗透性增加; ii)在Map3k7i AEC小鼠中,PAR-1诱导的肺血管渗透性在体内是不可逆的; iii)在Map3k7i AEC小鼠的EC中,β-连环蛋白表达显著降低;(4)糖原合成酶激酶-3 β(glycogen synthase kinase-3 β,GSK-3 β)在Map3k7i大肠癌小鼠的内皮细胞中具有持续活性,这可能是β-catenin在Map3k7i大肠癌小鼠的内皮细胞中表达显著降低的原因; v)PAR-1介导的TAK1活化在EC限制性STIM1敲除的EC中被阻止vi)令人惊讶的是,我们观察到SOCE通过EC中的TAK1活化而发出GSK-3 β失活的信号; vii)重要的是,PAR-1介导的肺血管渗漏在他莫昔芬诱导的EC限制性GSK-3 β敲除(GSK-3 β iEC)小鼠中显著减少。基于这些新的观察结果,在目标1中,我们将检验以下假设:继发于STIM 1介导的SOCE的TAK 1激活诱导STIM 1磷酸化,STIM 1磷酸化反过来抑制SOCE并抑制肺血管通透性。在目标2中,我们将检验以下假设:STIM1介导的SOCE继发的TAK1激活将GSK-3 β磷酸化为GSK-3 β,这反过来促进内皮AJs的β-连环蛋白表达增加,以恢复内皮屏障完整性,从而解决肺水肿。更好地理解SOCE下游TAK1功能的信号传导机制将导致解决脓毒症肺水肿的新治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHINNASWAMY TIRUPPATHI其他文献

CHINNASWAMY TIRUPPATHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHINNASWAMY TIRUPPATHI', 18)}}的其他基金

Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
  • 批准号:
    10488226
  • 财政年份:
    2021
  • 资助金额:
    $ 4.55万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10363718
  • 财政年份:
    2021
  • 资助金额:
    $ 4.55万
  • 项目类别:
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
  • 批准号:
    10297258
  • 财政年份:
    2021
  • 资助金额:
    $ 4.55万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10178835
  • 财政年份:
    2021
  • 资助金额:
    $ 4.55万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10586059
  • 财政年份:
    2021
  • 资助金额:
    $ 4.55万
  • 项目类别:
Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury
内皮细胞去泛素酶 A20 发出肺血管损伤修复信号
  • 批准号:
    9301023
  • 财政年份:
    2015
  • 资助金额:
    $ 4.55万
  • 项目类别:
TRPM2 mediates neutrophil transendothelial migration and inflammation
TRPM2介导中性粒细胞跨内皮迁移和炎症
  • 批准号:
    9260918
  • 财政年份:
    2015
  • 资助金额:
    $ 4.55万
  • 项目类别:
Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury
内皮细胞去泛素酶 A20 发出肺血管损伤修复信号
  • 批准号:
    9105412
  • 财政年份:
    2015
  • 资助金额:
    $ 4.55万
  • 项目类别:
Ca2+ Signaling, ICAM-1 Expression, and Lung Vascular Injury
Ca2 信号传导、ICAM-1 表达和肺血管损伤
  • 批准号:
    7457949
  • 财政年份:
    2007
  • 资助金额:
    $ 4.55万
  • 项目类别:
Cell Culture and Vector Core
细胞培养和载体核心
  • 批准号:
    7457951
  • 财政年份:
    2007
  • 资助金额:
    $ 4.55万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 4.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了